Novo Nordisk A/S: all 1,444 studies

Page 11 of 15. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.

• Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsCompletedNCT01561417Phase 1
• Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryCompletedNCT01561391Phase 4
• Efficacy and Safety of Activated Recombinant Human Factor VII in Refractory Haemorrhagic CystitisCompletedNCT01561352Phase 2
• Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis PatientsTerminatedNCT01559103Phase 1
• Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese SubjectsCompletedNCT01555749Phase 1
• Efficacy and Safety of Levemir® Used as Basal InsulinCompletedNCT01548248
• Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 TreatmentCompletedNCT01548235
• Observational Study to Evaluate the Safety of Levemir® in Patients With DiabetesCompletedNCT01545791
• Safety and Efficacy of Long-term Somatropin Treatment in AdultsCompletedNCT01543880
• Safety and Efficacy of Long-term Somatropin Treatment in ChildrenCompletedNCT01543867
• Observational Study of the Predictability of Levemir® in Terms of Metabolic Control, Change of Body Weight and HyposCompletedNCT01542489
• The Impact of Initiating/Switching to Insulin Detemir on Emotional Well-being and Treatment SatisfactionCompletedNCT01542476
• Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 DiabetesCompletedNCT01542463
• Pharmacokinetics of Insulin Detemir in Subjects With Type 1 DiabetesCompletedNCT01542450Phase 1
• An Observational Study in Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes MellitusCompletedNCT01542424
• Efficacy and Safety of Biphasic Insulin Aspart 30 for the Treatment of Type 2 Diabetes MellitusCompletedNCT01542060
• Special Survey for Patients With Type 1 or Type 2 DiabetesCompletedNCT01538589
• Paediatric Subjects - Special SurveyCompletedNCT01538576
• Insulin Profile of Biphasic Insulin Aspart 70 to That of Biphasic Insulin Aspart 30 in Healthy VolunteersCompletedNCT01538511Phase 1
• The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 DiabetesCompletedNCT01536665Phase 1
• Prandial Orientated Biphasic Insulin Aspart 30 Therapy - the Physiological Premix Insulin Therapy for Type 2 DiabetesCompletedNCT01536652
• Physiological Concept of Insulin Therapy in Subjects With Type 2 DiabetesCompletedNCT01536639
• Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the NetherlandsCompletedNCT01536626
• Post Marketing Surveillance Study of Biphasic Insulin Aspart 30CompletedNCT01536613
• Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 DiabetesCompletedNCT01536600
• Comparison of the Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 and Insulin Aspart in Subjects With Type 1 DiabetesCompletedNCT01536028Phase 1
• Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)CompletedNCT01530048Phase 1
• Genetic Testing of Noonan Subjects Previously Treated With Norditropin®. An Extension to Trial GHNOO-1658CompletedNCT01529944Phase 3
• Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan SyndromeCompletedNCT01529840Phase 3
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy SubjectsCompletedNCT01527656Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy SubjectsCompletedNCT01527643Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Japanese SubjectsCompletedNCT01527630Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 70 in Healthy Male SubjectsCompletedNCT01527565Phase 1
• Bioequivalence of Two Formulations of Biphasic Insulin Aspart 50 in Healthy Male SubjectsCompletedNCT01527552Phase 1
• Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Subjects With Type 2 DiabetesCompletedNCT01527539Phase 3
• Glycaemic Control of Biphasic Insulin Aspart 70 and 30 in Subjects With Type 2 DiabetesCompletedNCT01526980Phase 2
• Comparison of Single Dose and Steady State Pharmacodynamics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 DiabetesCompletedNCT01526941Phase 1
• Pharmacokinetics of Biphasic Insulin Aspart 30 and 70 in Subjects With Type 1 DiabetesCompletedNCT01524809Phase 1
• Comparison of Two Formulations of Biphasic Insulin Aspart 70CompletedNCT01523041Phase 1
• Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy SubjectsCompletedNCT01520831Phase 1
• Comparison of Biphasic Human Insulin 30 With Biphasic Insulin Aspart in Subjects With DiabetesCompletedNCT01520818Phase 3
• Comparison of Two Biphasic Insulin Aspart Treatments in Subjects With Type 2 DiabetesCompletedNCT01520753Phase 3
• Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pHCompletedNCT01518166Phase 1
• Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner SyndromeCompletedNCT01518062Phase 4
• Use of Somatropin in Turner SyndromeCompletedNCT01518036Phase 3
• Metabolism and Excretion of Liraglutide in Healthy Male VolunteersCompletedNCT01517568Phase 1
• Effect of Liraglutide on Absorption of Paracetamol in Subjects With Type 2 DiabetesCompletedNCT01517555Phase 1
• Effect of Liraglutide on Heart Frequency in Healthy VolunteersCompletedNCT01516255Phase 1
• Evaluation of Safety and Parameters of Application TechniqueCompletedNCT01516242
• Special Survey for Long Term ApplicationCompletedNCT01516229
• Safety and Tolerability of Liraglutide in Healthy Japanese Male VolunteersCompletedNCT01515592Phase 1
• Comparison of Two Liraglutide Formulations in Healthy SubjectsCompletedNCT01515579Phase 1
• Bioequivalence of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01515553Phase 1
• First Human Dose Trial of NNC0195-0092 (Somapacitan) in Healthy SubjectsCompletedNCT01514500Phase 1
• Comparison of Three Liraglutide Formulations in Healthy VolunteersCompletedNCT01514487Phase 1
• Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy VolunteersCompletedNCT01513525Phase 1
• Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult VolunteersWithdrawnNCT01512095Phase 1
• Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesCompletedNCT01511692Phase 1
• Efficacy and Safety of Metformin and Liraglutide in Obese Subjects With Type 2 Diabetes Previously Treated With an Oral Hypoglycemic AgentCompletedNCT01511198Phase 2
• Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control GroupCompletedNCT01511185Phase 1
• Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 DiabetesCompletedNCT01511172Phase 2
• Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersCompletedNCT01511159Phase 1
• Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 DiabetesCompletedNCT01509755Phase 2
• Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 DiabetesCompletedNCT01509742Phase 1
• Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 DiabetesCompletedNCT01508949Phase 2
• Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 DiabetesCompletedNCT01508923Phase 2
• Comparison of Two Liraglutide Formulations in Healthy VolunteersCompletedNCT01508897Phase 1
• Influence on the Effect of an Oral Contraceptive Drug After Administration of Liraglutide in Postmenopausal WomenCompletedNCT01508858Phase 1
• Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney FunctionCompletedNCT01508806Phase 1
• Vagifem® Used for the Treatment of Atrophic Vaginitis Due to Oestrogen DeficiencyCompletedNCT01507454
• Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver FunctionCompletedNCT01507389Phase 1
• Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy VolunteersCompletedNCT01507337Phase 1
• Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 DiabetesCompletedNCT01507311Phase 1
• Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 DiabetesCompletedNCT01507285Phase 1
• Safety and Tolerability of Liraglutide in Healthy Male VolunteersCompletedNCT01507272Phase 1
• Diabetes Attitudes Wishes and NeedsCompletedNCT01507116
• Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing CountriesCompletedNCT01503567
• Pharmacokinetics of Somatropin in Patients With End Stage Renal Disease Receiving Chronic HaemodialysisCompletedNCT01502137Phase 1
• Safety and Efficacy of Somatropin in Children With Growth Hormone DeficiencyCompletedNCT01502124Phase 3
• Observational Study of Norditropin NordiFlex® With NordiFlex PenMate™CompletedNCT01500486
• Pharmacokinetics of Insulin Detemir in Healthy Chinese Male SubjectsCompletedNCT01498939Phase 1
• Comparison of Two Insulin Detemir Formulations in Healthy VolunteersCompletedNCT01498926Phase 1
• Observational Study of NovoNorm® in Subjects With DiabetesCompletedNCT01498913
• An Observational Study Evaluating Efficacy, Safety and Convenience of NovoNorm® in Treatment of Type 2 Diabetes in Routine Clinical PracticeCompletedNCT01498900
• Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesCompletedNCT01497600Phase 1
• Pharmacokinetics of Insulin Detemir in Healthy Volunteers From TaiwanCompletedNCT01497587Phase 1
• Within-subject Variability of Insulin Detemir in Children and Adolescents With Type 1 DiabetesCompletedNCT01497574Phase 1
• Pharmacodynamics and Pharmacokinetics of Insulin Detemir in Subjects With Type 2 DiabetesCompletedNCT01497561Phase 1
• Within-subject Variability of Insulin Detemir in Healthy VolunteersCompletedNCT01497535Phase 1
• To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1CompletedNCT01493388
• Observational Study With InnoLet® in Daily Clinical PracticeCompletedNCT01492959
• Observational Study With Mixtard® 30 NovoLet® to Assess Patient SatisfactionCompletedNCT01492218
• NovoLet® Acceptance Study Within the Hospital Practise in IndonesiaCompletedNCT01492205
• Observational Study on Efficacy, Safety and Convenience of Using Mixtard® 30 NovoLet® Alone or Combined With OHA in Treatment of Type 2 Diabetes in Routine Clinical PracticeCompletedNCT01492166
• NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaCompletedNCT01492153
• Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Fed Healthy VolunteersCompletedNCT01490658Phase 1
• Surveillance Study of NovoRapid® for New Drug Re-examinationCompletedNCT01490112
• Comparison of Insulin Detemir Produced by the Current Process and the NN729 Process in Healthy SubjectsCompletedNCT01490099Phase 1
• Single Dose Pharmacokinetics of Repaglinide, Metformin and Combination Tablet in Healthy VolunteersCompletedNCT01489644Phase 1
• Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy VolunteersCompletedNCT01487811Phase 1

← Novo Nordisk A/S overview and focus areas